Phosphaplatin compounds as immuno-modulatory agents and therapeutic uses thereof
AssigneePhosplatin Therapeutics LLC
InventorsTyler Ames, Matthew Price
Life of this patent
Estimating the term…
Abstract
Use of (pyrophosphato)platinum(II) or platinum(IV) complexes (“phosphaplatins”), especially 1,2-cyclohexanediamine(pyrophosphato) platinum(II), as immunogenic cell death (ICD) inducing agents and their combination with immune checkpoint protein inhibitors for treatment of cancers, and the mechanistic rationale for the methods thereof, are disclosed.
Claims19
A method for treating a subject having cancer, comprising administering to the subject a therapeutically effective amount of a phosphaplatin compound having a structure of formula I or II:
- or a pharmaceutically acceptable salt thereof, to induce immunogenic cell death (ICD) in the subject, and a therapeutically effective amount of an immune checkpoint protein inhibitor, wherein R1 and R2 are each independently selected from NH3, substituted or unsubstituted aliphatic amines, and substituted or unsubstituted aromatic amines;
- and wherein R3 is selected from substituted or unsubstituted aliphatic diamines, and substituted or unsubstituted aromatic diamines.
A method for treating a subject having cancer, comprising administering to the subject a therapeutically effective amount of a phosphaplatin compound having a structure of formula III or IV:
- or a pharmaceutically acceptable salt thereof, to induce immunogenic cell death (ICD) in the subject, and a therapeutically effective amount of an immune checkpoint protein inhibitor, wherein R1 and R2 are each independently selected from NH3, substituted or unsubstituted aliphatic amines, and substituted or unsubstituted aromatic amines;
- and wherein R3 is selected from substituted or unsubstituted aliphatic diamines, and substituted or unsubstituted aromatic diamines.
Dependencies are inferred from the claim text.